A Group of Hypermethylated miRNA Genes in Breast Cancer and Their Diagnostic Potential
- Авторы: Filippova E.A.1, Loginov V.I.1,2, Pronina I.V.1, Khodyrev D.S.3, Burdennyy A.M.1, Kazubskaya T.P.4, Braga E.A.1,2
-
Учреждения:
- Institute of General Pathology and Pathophysiology
- Research Center of Medical Genetics
- Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medico-Biological Agency of Russia
- Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- Выпуск: Том 53, № 3 (2019)
- Страницы: 371-378
- Раздел: Genomics. Transcriptomics
- URL: https://journals.rcsi.science/0026-8933/article/view/163935
- DOI: https://doi.org/10.1134/S0026893319030051
- ID: 163935
Цитировать
Аннотация
miRNA genes play an important role in cancer pathogenesis, while they may be suppressed by hypermethylation. Here, we assess the diagnostic potential of a group of hypermethylated miRNA genes (MIR-124-1, MIR-124-3, MIR-125B-1, MIR-127, MIR-132, MIR-193a, and MIR-34b/c) in a representative set of 70 breast cancer samples and 17 breast tissue samples from deceased donors with no malignancies. For these seven genes, the methylation status is determined using the methylation-specific PCR. Methylation reached 26–76% in tumor specimens, 1‒27% in paired considered normal breast tissues, and 0–18% in breast tissue from deceased donors. By quantitative RT-PCR, reduced expression levels of the investigated miRNAs are detected, with a negative correlation of expression levels with gene hypermethylation. Combinations of three or four hypermethylation biomarkers, namely, MIR-124-1, MIR-125B-1, MIR-127, and MIR-34b/c are found suitable for breast cancer diagnostics; with sensitivity (76‒93%), specificity (88‒100%), and AUC (0.88‒0.94). Notably, the MIR-127 gene was hypermethylated only in the tumor samples of patients with metastases, and, therefore, should be tested as a marker of breast cancer dissemination. These findings may lead to improvement in the management of breast cancer.
Ключевые слова
Об авторах
E. Filippova
Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315
V. Loginov
Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315; Moscow, 115478
I. Pronina
Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315
D. Khodyrev
Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies,Federal Medico-Biological Agency of Russia
Email: eleonora10_45@mail.ru
Россия, Moscow, 115682
A. Burdennyy
Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315
T. Kazubskaya
Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow, 115478
E. Braga
Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics
Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow, 125315; Moscow, 115478
Дополнительные файлы
